SPU-26 Pain Management Using Ketamine Composition Action supports planned IND package submission to FDA for SP-26 ENGLEWOOD CLIFFS, NJ, March 27, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (the “Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent…


Previous articleReunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting
Next articleRevive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder